Balyasny Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Balyasny Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,500	Closed	-$822K	–	2887
2025 Q4	$822K	Sell	4,500 -2,000	-31%	-$279K	﹤0.01%	2282
2025 Q3	$789K	Buy	6,500 +1,400	+27%	+$158K	﹤0.01%	2216
2025 Q2	$532K	Sell	5,100 -1,800	-26%	-$191K	﹤0.01%	2272
2025 Q1	$805K	Buy	+6,900	New	+$786K	﹤0.01%	2086
2024 Q4	–	Sell	-4,700	Closed	-$422K	–	2725
2024 Q3	$422K	Buy	+4,700	New	+$410K	﹤0.01%	2333
2023 Q3	–	Sell	-39,000	Closed	-$2.8M	–	2251
2023 Q2	$2.8M	Buy	+39,000	New	+$2.88M	0.01%	1261
2020 Q4	–	Sell	-40,000	Closed	-$2.85M	–	1319
2020 Q3	$2.85M	Buy	+40,000	New	+$3.12M	0.02%	745

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Balyasny Asset Management's AXSM Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 76,250 shares worth $18.7M. The stake represents 0.02% of the portfolio and ranks #753 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in AXSM as recently as Q1 2025.

Balyasny Asset Management first reported a position in AXSM in Q1 2018 and has held it in 9 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Balyasny Asset Management held 76,250 shares of Axsome Therapeutics worth $18.7M as of Q2 2026.
Axsome Therapeutics was a new Balyasny Asset Management position in Q2 2026.
Axsome Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q2 2026, its #753 holding.
Balyasny Asset Management first reported a position in Axsome Therapeutics in Q1 2018 and has held it in 9 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.